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Purpose: To describe the damage to the muscles and propose a pathophysiologic mechanism for muscle atrophy
and weakness after mantle field radiotherapy in Hodgkin lymphoma (HL) survivors.
Methods and Materials: We examined 12 patients treated by mantle field radiotherapy between 1969 and 1998.
Besides evaluation of their symptoms, the following tests were performed: dynamometry; ultrasound of the ster-
nocleidomastoid, biceps, and antebrachial flexor muscles; and needle electromyography of the neck, deltoid, and
ultrasonographically affected arm muscles.
Results: Ten patients (83%) experienced neck complaints, mostly pain and muscle weakness. On clinical examina-
tion, neck flexors were more often affected than neck extensors. On ultrasound, the sternocleidomastoid was se-
verely atrophic in 8 patients, but abnormal echo intensity was seen in only 3 patients. Electromyography of the
neck muscles showed mostly myogenic changes, whereas the deltoid, biceps, and antebrachial flexor muscles
seemed to have mostly neurogenic damage.
Conclusions: Many patients previously treated by mantle field radiotherapy develop severe atrophy and weakness
of the neck muscles. Neck muscles within the radiation field show mostly myogenic damage, and muscles outside
the mantle field show mostly neurogenic damage. The discrepancy between echo intensity and atrophy suggests
that muscle damage is most likely caused by an extrinsic factor such as progressive microvascular fibrosis. This
is also presumed to cause damage to nerves within the radiated field, resulting in neurogenic damage of the deltoid
and arm muscles.  2012 Elsevier Inc.
Hodgkin lymphoma, Dropped head syndrome, Mantle field radiotherapy, Muscle damage, Muscle ultrasound.
INTRODUCTION
The survival of Hodgkin lymphoma (HL) patients has im-
proved significantly during the past decades, with 70–97%
of the present cases being cured (1–3). With longer follow-
up, it has become apparent that survivors of HL carry risks
for treatment-related side effects that may not manifest until
many years later (4, 5). In patients previously treated by
radiotherapy (RT), cardiovascular complications and
secondary malignant tumors have the greatest impact on the
patients’ survival and have been extensively investigated
(6–9).
Less frequently reported late effects are atrophy and weak-
ness of the muscles within the radiation fields (10–14). A
considerable number of HL survivors report pain, stiffness,
or weakness of the muscles; in two reports, 25% and 50%
of patients treated by mantle field RT experience these
problems after a mean of 10 and 19 years of follow-up (15,
16). Although the mantle field technique has been replaced
in recent years by less extensive radiation fields, many
patients are still alive who have been treated by this
method. As an estimate, 573 HL survivors were treated by
RT including the mantle field in a large trial from 1993 to
1999 in eight European countries (3). The 10-year overall sur-
vival was 92% and 84% for patients with favorable and unfa-
vorable features, respectively (3), leaving about 500 patients
still alive who were treated during this period with mantle
field RT. Furthermore, in a recent cohort study performed in
four centers in The Netherlands, 1,415 HL survivors were
identified who were treated by mantle field RT between
1965 and 1995 (7).
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Muscular symptoms of the neck and shoulder areas have
a long-onset latency (12, 13). Inasmuch as weakness
may be progressive, clinicians dealing with HL survivors
will be confronted with these symptoms and should have
knowledge about the treatment and prognosis of these late
effects. The aim of this study was to gain more insight into
the pathophysiology and the clinical picture of muscle
atrophy in HL survivors treated by the mantle field
technique. Furthermore, we give suggestions for the
management of these late effects.
METHODS AND MATERIALS
Patients
Between November 2007 and August 2008, 81 HL survivors
were enrolled in a study to evaluate the late sequelae of treatment.
Ethical approval was given by the Institutional Review Board of the
St. Antonius hospital, Nieuwegein. All HL survivors registered at
our institution who were free of disease and had been followed
up for more than 2 years from the diagnosis of HL were invited
to participate (n = 113). Nineteen HL survivors were deceased; 7
HL survivors did not attend their regular checkups and could not
be traced. Another 6 HL survivors declined participation because
of old age (n = 3), long traveling distance (n = 1), or no specific
reason (n = 2).
Part of this study included neurologic examination including de-
termination of muscle strength. Twenty patients had been irradiated
by mantle field RT (Table 1). They were all considered candidates
for the current study. Three patients were not invited to participate
because of recently diagnosed metastatic malignancy (n = 2) or
end-stage heart failure (n = 1). Five of the remaining 17 patients
refused participation because of long traveling distance (n = 3), ad-
vanced age (n = 1), and absence of neck symptoms (n = 1). Twelve
patients (8 women and 4 men) gave informed consent (Fig. 1). The
baseline characteristics did not differ from those of the HL
survivors treated by mantle field RT who were not included.
Treatment characteristics
In all patients the total RT dose to the mantle field was 40 Gy in
20 fractions of 2 Gy, given in anterior-posterior and posterior-
anterior fields on alternate days. Over the years the RT techniques
have changed. Until 1976, a cobalt-60 unit was used, and after that
a 6 to 10-MV linear accelerator was used. Three patients were also
treated with chemotherapy.
Clinical examination
All patients were examined according to a standardized protocol.
A detailed history was taken about previous neurologic symptoms
or operations before treatment for HL. Patients were asked to fill in
a customized questionnaire including all neurologic symptoms and
functional impairments we had encountered in the whole group.
Furthermore, two standardized questionnaires were distributed:
the Neck Disability Index to enquire about neck symptoms (17)
and the Checklist Individual Strength-20 (CIS-20) to examine fa-
tigue (18).
A detailed clinical examination was performed by a senior staff
neurologist (O.J.M.V.). Strength of the neck flexor muscles was as-
sessed with the patient in supine position, and the neck extensors
with the patient in a prone position. Both were graded according
to the Medical Research Council (MRC) scale (19).
Muscle strength was also measured with a hand-held dynamom-
eter (Citec dynamometer CT 3001, C.I.T. Technics, Groningen, The
Netherlands) in five different muscle groups (neck flexors, neck ex-
tensors, shoulder abductors, elbow flexors, and grip strength). Max-
imum muscle strength was tested using the break method, in which
the examiner gradually overcomes the muscle strength of the pa-
tient and stops at the moment the extremity gives way (20). Grip
Table 1. Baseline characteristics of the total cohort of 81 Hodgkin lymphoma survivors
Characteristic
Treatment
Mantle field RT
(n = 20)
RT on the neck only
(n = 19)
No RT on the neck
(n = 42)
Sex, male 10 10 28
Age (y)  SD 53  10 40  11 49  13
RT dose (Gy)  SD 40  1* 36  4y –
Follow-up since diagnosis (y)  SD 23  8 9  5 11  7
Patients with neck muscle weakness, total 17 (83%) 4 (21%) 4 (10%)
Patients with neck muscle weakness according to follow-up (y) since RT
<10 – 0/13
1019 6/8 4/6
2029 7/8 –
>30 4/4 –
Abbreviations: RT = radiotherapy; SD = standard deviation.
* Dose to the mantle.
y Dose to the neck.
20 patients treated by  
mantle field radiotherapy 
3 not invited to participate: 
-2 metastatic malignancy  
-1 heart failure 
5 refused to participate 
12 patients treated by mantle field radiotherapy 
included: 
-10 with neck weakness     
-2 without neck weakness 
Fig. 1. Selection of study population.
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strength was measured using the make method, requiring the pa-
tient to exert maximal pressure on the dynamometer. In each patient
everymuscle group was measured three times and the average score
was calculated. Results under the 5th percentile of the normal pop-
ulation (adjusted for sex) were considered abnormal (21).
Ancillary investigations
Quantitative muscle ultrasound. Muscle ultrasound examina-
tions were performed on the sternocleidomastoid, the biceps, and
the antebrachial flexor muscles using a standard technique and nor-
mal values as described previously (22, 23). A broadband linear 5-
to 17-MHz transducer (Philips IU22, The Netherlands) was used.
All system-setting parameters were kept constant throughout the
study (gain 70 dB, compression 55, no adjustments in time gain
compensation or focus). For echo intensities, three consecutive
measurements were taken of every muscle under study, and the re-
sults were averaged. The mean muscle echo intensity was calcu-
lated from a region of interest comprising as much muscle tissue
as possible without the surrounding fascia, using a histogram-
based grey-scale analysis with 256 grey levels (23). Muscle
thickness was measured with electronic calipers. Increased echo
intensity is indicative of an intrinsic muscle disease (24).
To compare individual patients and muscles in this study, echo
intensity and muscle thickness were transformed into Z scores.
The Z score reflects the number of standard deviations a measure
deviates from normal, given a certain age and sex. Abnormal
echo intensity for individual muscles was defined as a Z score of
more than 2. For muscle atrophy, the same cutoff value was used
(Z score below 2).
Nerve conduction studies and needle electromyography. Elec-
trophysiologic examination was performed using standard tech-
niques with a Medelec Synergy electromyography (EMG) system
(Viasys, OxfordMedical Instruments, Surrey, UK). Both nerve con-
duction studies and needle EMGwere performed according to stan-
dardized clinical protocols for the detection of polyneuropathy and
myopathy. Findings were compared to normal values from our cen-
ter’s database. Nerve conduction studies included sensory nerve ac-
tion potential (SNAP) amplitude and nerve conduction velocity of
both median nerves to the third digit and both superficial radial
nerves. Needle EMG of the splenius capitis, sternocleidomastoid,
and deltoid muscles was performed bilaterally in all patients. Addi-
tional needle EMG was performed of the biceps and antebrachial
flexor muscles if they showed abnormal echo intensity on ultra-
sound.
Statistical analysis
Statistical analysis was performed using SPSS version 15.0
(SPSS Inc., Chicago, IL). One-sample t-tests were conducted for
comparison between the echo intensity or muscle thickness
Z scores and 0 (the standardized value for certain age and sex).
RESULTS
HL survivors
Baseline characteristics of the HL survivors (n = 81) are
presented in Table 1. Neck muscle weakness revealed by
clinical examination had a prevalence of 31%, being highest
in the subgroup of patients treated by mantle field RT: 85%.
This high percentage was not found in patients treated by RT
to the neck only (25%). These patients were treated more re-
cently and with lower-dose RT, reflecting a change in the
treatment approach during more recent years. The percent-
age of patients with neck weakness increased from 0% (0/
13) in patients irradiated less than 10 years ago to 71%
(10/14), 88% (7/8), and 100% (4/4) in patients irradiated be-
tween 10 and 20 years ago, 20 and 30 years ago, and more
than 30 years ago, respectively.
Mantle field subgroup
Demographic data of the subgroup of 12 mantle field pa-
tients are presented in Table 2. Nine patients had other
Table 2. Demographic characteristics of 12 Hodgkin lymphoma survivors treated by mantle field radiotherapy
Patient
Age
(y) Sex
Treatment
year Chemotherapy Comorbidity
MRC grade
neck flexors
1 62 M 1973 No Aortic valve stenosis, RT induced
osteoporosis, cervical spine arthrodesis
4
2 58 M 1982 No Aortic valve stenosis, myocardial infarction 3
3 47 F 1983 Yes
3 MOPP
Lung fibrosis, thyroid dysfunction 3
4 60 M 1981 No Atherosclerosis carotid artery, CAD, thyroid
dysfunction, osteoporosis, esophageal stricture
2
5 58 F 1985 Yes
3 MOPP
Breast cancer, thyroid dysfunction, persistent
tachycardia
2
6 62 F 1993 No – 3+
7 52 M 1969 No CAD, constrictive pericarditis, thyroid cancer,
lung fibrosis
3+
8 47 F 1978 No Breast cancer, thyroid dysfunction, constrictive
pericarditis, aortic valve replacement
3+
9 34 F 1997 No Lung fibrosis, thyroid dysfunction 3+
10 50 F 1987 No Breast cancer, CAD, thyroid dysfunction 4
11 55 M 1991 Yes
8 MOPP/ ABV
– 5
12 48 M 1985 No – 5
Abbreviations: RT = radiotherapy; MRC = Medical Research Council scale; MOPP = mechlorethamine, vincristine, prednisone, procar-
bazine; CAD = coronary artery disease; ABV = doxorubicin, bleomycin, vinblastin.
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comorbidities within the radiation field, including three
women with breast cancer treated by mastectomy.
Neck symptoms were present in 10 patients. (Table 3).
They reported pain and fatigue in the neck muscles which al-
ready started a few years after RT. Neck symptoms were
constantly present in 2 patients and were triggered by activ-
ities during which the head had to be held in the same posi-
tion for more than 30 minutes in 8 patients. The patients
experienced more frequent headaches than before receiving
RT; they also experienced pain and weakness in the shoul-
ders and arms. Because of these symptoms, patients were
particularly disabled in the following activities: walking
for more than 30 minutes, swimming, lifting the head while
in a supine position, driving a car, working on the computer,
reading, and lifting heavy bags. Ten patients were using pain
medication for neck pain on a regular basis, or had repeat-
edly consulted a physiotherapist with satisfactory but only
temporary relief.
On the CIS-20 scale, 10 patients had mean scores exceed-
ing 35 points, meeting the criterion for chronic fatigue. On
the Neck Disability Index, the mean and median scores of
the total group were 14 and 17 (range, 0–25) (Table 3).
Clinical examination
The 10 patients with neck symptoms were found to have
neck flexor weakness on clinical examination. This was
graded 2–4+ on the MRC scale. Neck extension was less of-
ten impaired in 6 of the 12 patients. In 2 patients a dropped
head syndrome was observed, signifying a Grade <3 paresis
on the MRC scale (i.e., a disability of the neck extensors to
overcome gravity in prone position). On muscle dynamom-
etry, muscle weakness in one or more of the investigated
muscles was found in all but 4 patients (Table 3).
Muscle ultrasound
Muscle ultrasound showed atrophy of the sternocleido-
mastoid muscles in all but 1 patient. The mean Z score of
this muscle was 2.27, significantly lower than in the nor-
mal population (p < 0.01). In contrast with the decrease in
muscle volume, the echo intensity was rarely above 2 stan-
dard deviations in the sternocleidomastoid muscles. Abnor-
mal findings on ultrasound were rare in the muscles outside
the radiation field (Table 3).
Nerve conduction studies
Nerve conduction studies showed abnormalities in 6 pa-
tients, of whom only 1 had been treated by chemotherapy
(Patient 11). One patient had low SNAP amplitudes and bor-
derline low conduction velocities of all investigated nerves.
Another patient had borderline low amplitude SNAP of the
superficial radial nerves on both sides and borderline low
nerve conduction velocities of both median nerves. Three
patients had low SNAP amplitudes of the superficial radial
nerves; in 1 patient this was present unilaterally. Finally, 1
patient had isolated low nerve conduction velocity of the
right median nerve at the wrist segment, compatible with
a (subclinical) carpal tunnel syndrome unrelated to the RT.
Needle EMG
Needle EMG showed abnormal findings in the majority of
the neck and deltoid muscles. Abnormalities were less prev-
alent in the biceps and antebrachial flexor muscles (Table 3).
Myogenic changes (small amplitude, short-duration mo-
tor unit action potentials) were most prevalent in the cervical
muscles, occurring in 11 patients (Fig. 2). Only 1 patient
showed light neuropathic changes (large amplitude, long-
duration motor unit action potentials) in the neck muscles.
The deltoid muscles showed mostly neuropathic abnormali-
ties in 6 patients, whereas myogenic changes and mixed
changes were present in 3 patients and 1 patient, respec-
tively. The biceps and antebrachial flexor muscles showed
neuropathic damage in all patients investigated except for
1 patient. No spontaneous activity pointing to denervation
Table 3. Results in 12 Hodgkin lymphoma survivors treated
by mantle field radiotherapy
Investigation Abnormal findings (n)
Questionnaire about neck symptoms:
Neck pain 9 (75%)
Tired feeling in the neck muscles 7 (58%)
Hanging neck 7 (58%)
Thinner neck 9 (75%)
Neck Disability Index 9 (75%)
Severely disabled (score 25–34) 1 (8%)
Moderately disabled (score 15–24) 5 (42%)
Mildly disabled (score 5–14) 3 (25%)
CIS-20 10 (83%)
Clinical examination (MRC scale)
Neck flexors 10 (83%)
Neck extensors 6 (50%)
Dynamometry
Neck flexors 8 (67%)
Neck extensors 4 (33%)
Shoulder abductor 8 (67%)
Elbow flexors 5 (42%)
Antebrachial flexors 2 (17%)
Echo intensity
Sternocleidomastoid muscles 3 (25%)
Biceps muscles 3 (25%)
Antebrachial flexor muscles 3 (25%)
Diameter
Sternocleidomastoid muscles 8 (67%)
Biceps muscles 1 (8%)
Antebrachial flexor muscles 0
Needle EMG
Sternocleidomastoid muscles 12 (100%)
Splenius capitis muscles 12 (100%)
Deltoid muscles 10 (83%)
Biceps muscles 2 (17%)
Antebrachial flexors 5 (42%)
Nerve conduction studies
SNAP amplitude median nerves 1 (8%)
SNAP amplitude radial nerves 5 (42%)
Conduction velocity median nerves 2 (25%)
Conduction velocity radial nerves 1 (8%)
Abbreviations: CIS-20 = Checklist Individual Strength-20;
MRC = Medical Research Council scale; EMG = electromyogra-
phy; SNAP = sensory nerve action potential.
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or myositis was found in any of the patients, but 2 patients
showed myokymia, 1 in the right deltoid and the other in
the right sternocleidomastoid muscle.
DISCUSSION
Clinical findings
Neck muscle weakness is a very frequent late complica-
tion in HL survivors treated with mantle field RT, occurring
in 85% of the patients in our cohort. Patients with impaired
neck muscle strength have a large scale of symptoms, which
negatively influence their daily activities and result in in-
creased fatigue scored on the CIS-20 scale. Mantle field
RT survivors with preserved neck muscle strength do not ex-
perience such severe symptoms.
All patients diagnosed with cervical muscle weakness
were radiated more than 10 years ago, and most patients
(11/12) had an onset latency of more than 15 years. These
findings are in line with previous reports describing symp-
tomatic neck muscle weakness mostly occurring more than
10 years after RT (13). The progressive character of the mus-
cle damage is shown by the fact that no patients irradiated
less than 10 years ago had weakness, compared to dimin-
ished strength in all survivors treated more than 30 years
ago. Longer follow-up of patients treated by more recent ra-
diation techniques and lower dose will show whether these
patients will also develop cervical muscle weakness.
Few reports on HL survivors with impaired neck muscle
strength describe patients with neck extensor weakness, pre-
senting with a dropped head syndrome (13, 25). Clinically,
we found predominantly neck flexor weakness. When we
examined the neck flexors and extensors by needle EMG,
all patients showed an equal amount of abnormalities in
both muscle groups, suggesting that both the anterior and
the posterior neck compartments are equally affected by RT.
To our knowledge, our study is the first to perform system-
atic testing of all neck muscles in an unselected group of pa-
tients who have received mantle field treatment. Typically,
patients do not consult their physicians because of neck
flexor weakness because this manifests in impairment of lift-
ing the head from the pillow or maintaining head position
when swimming on the back, and these are not very debili-
tating symptoms, in contrast to the dropped head syndrome
that occurs when severe damage to the neck extensors de-
velops (26).
Two mantle-field irradiated HL survivors did not show
neck muscle weakness at all. After receiving RT, they had
both engaged in sport activities in which the neck muscles
are trained (rowing and water polo). Possibly, muscle
strength training may have prevented neck muscleweakness.
Interestingly, they showed no late sequelae in other struc-
tures, either (cardiac valves, carotid wall, thyroid gland).
Apparently, some patients are less vulnerable to radiation-
induced damage in these tissues, possibly because of genetic
differences in radiosensitivity (27).
Pathophysiology
There is no consensus about the cause of the muscle atro-
phy in the few studies performed so far. Several theories
have been proposed based on a small number of cases (10,
11, 13, 28, 29). Some findings have been consistent with
primary damage to the neurons, others showed primary
damage to the muscles or to extrinsic factors like the
vasculature or the connective tissue respectively.
In our study the sternocleidomastoid muscle was severely
atrophic in 67% of patients, and the group as a whole had
a significant lower diameter (and thus volume) of this muscle
in comparison to the general population. The discrepancy
between this severe atrophy and the mostly normal echo in-
tensity suggests that muscle damage is most likely caused by
an extrinsic factor (e.g., progressive microvascular fibrosis).
This was hypothesized earlier by Fajardo et al., who showed
that capillaries are susceptible to radiation damage (30).
Needle EMG of the neck muscles in the radiation field
showed mostly myogenic changes, with small motor units
consistent with the amount of atrophy found. This pattern
has also been found by others (10, 11, 13), but our study
includes the largest number of patients and shows
a consistent pattern of myogenic changes in 71% of the
muscles entirely situated within the radiation field. Twenty
percent of the neck muscles showed neuropathic or mixed
changes, which can presumably also be explained by
vascular injury triggering nerve damage.
The deltoid muscles, which are partially in the radiation
field, and the muscles entirely outside the radiation field
seemed to have mostly neuropathic damage on needle
EMG, suggesting primary affection of the nerve roots and
brachial plexus, which are situated in the radiation field for
a long distance. The axillary nerves that innervate the deltoid
muscles are especially prone to injury because they have
a smaller diameter and are situated in the axilla, which re-
ceives a substantial amount of the radiation (31). Only 1 of
the 3 patients who were treated by chemotherapy showed
neuropathic changes, so this did not substantially contribute
to this finding. The myogenic changes in the deltoid muscles
Fig. 2. Results of needle electromyography (EMG).
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could have been directly caused by radiation to these mus-
cles, inasmuch as there is some dispersion of radiation, as
shown in dosimetry studies (31).
We did not performmuscle biopsy in these patients to con-
firm our hypothesis. However, a myogenic origin of damage
in irradiated muscles was shown in four previous reports an-
alyzing muscle biopsy specimens (10–12). One case report
describing the trapezius muscle in a 42-year-old HL
survivor previously treated by mantle field RT was
suggestive of nemaline myopathy (12). This disorder, char-
acterized by muscle atrophy and intracytoplasmatic rod for-
mation in the myofibers, has been observed in a variety of
settings (e.g., polymyositis, spinal progressive muscle atro-
phy, acute alcoholic myopathy) when the congenital and fa-
milial types, which are most frequent, are discounted.
However, it is also a known phenomenon in muscle aging
(32), possibly suggesting that RT induces accelerated muscle
aging. This disorder was, however, not described in other HL
survivors with muscle weakness. Two other studies perform-
ing muscle biopsies in irradiated patients are suggestive of
muscular damage (10, 11). Unfortunately, biopsy
specimens were taken from the deltoid muscle, which is
not completely within the radiation field (11). Furthermore,
Aggarwal et al. conclude, after extensive investigations in-
cluding muscle biopsies, that the cause of the muscle atrophy
is myogenic, but their report was presented only as an ab-
stract and did not state from which muscles the biopsy spec-
imens were taken (10). Another case study describes
a muscle biopsy from a deltoid muscle in a patient who
had been treated by whole-body RT, a highly uncommon
treatment modality for HL. The muscle biopsy revealed
chronic neurogenic reinnervation (13).
Clinical implications
Until now, therapy has been focused on supportive care
measurements like soft neck collars or surgery (posterior
spinal arthrodesis) in more severe cases (26). Based on our
hypothesis that primary vascular injuries may cause myo-
genic damage in the muscles in the radiation field, we rec-
ommend training of the affected muscles. It is hoped that
this may promote increased vascularization of the muscles
by the formation of collateral vessels, which can contribute
to maintaining muscle strength and integrity. Our theory is
supported by the fact that the 2 patients who received mantle
field irradiation but did not experienced neck weakness per-
formed sports during which the neck muscles are intensively
trained. Moreover, patients visiting a physiotherapist on
a regular basis report beneficial results from performing reg-
ular training exercises.
Currently, we refer our patients with neck weakness to an
academic rehabilitation center where they can undergo a suit-
able muscle strength training program aiming at reduction of
neck symptoms and gain of muscle strength. Further studies
are needed in which HL survivors who received mantle field
irradiation are randomized between training on a regular ba-
sis vs. no training.
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